Sign In
Buy HBIO
Harvard Bioscience Earnings Calls
| Release date | Nov 06, 2025 |
| EPS estimate | $0.0400 |
| EPS actual | -$0.0100 |
| EPS Surprise | -125.00% |
| Revenue estimate | 23.1M |
| Revenue actual | 20.591M |
| Revenue Surprise | -10.86% |
| Release date | Aug 11, 2025 |
| EPS estimate | -$0.0250 |
| EPS actual | -$0.0100 |
| EPS Surprise | 60.00% |
| Revenue estimate | 19M |
| Revenue actual | 20.45M |
| Revenue Surprise | 7.63% |
| Release date | May 12, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0100 |
| EPS Surprise | 50.00% |
| Revenue estimate | 21.4M |
| Revenue actual | 21.774M |
| Revenue Surprise | 1.75% |
| Release date | Mar 12, 2025 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0600 |
| EPS Surprise | 20.00% |
| Revenue estimate | 20.95M |
| Revenue actual | 24.556M |
| Revenue Surprise | 17.21% |
Last 4 Quarters for Harvard Bioscience
Below you can see how HBIO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 12, 2025 |
| Price on release | $0.685 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0600 |
| EPS surprise | 20.00% |
| Date | Price |
|---|---|
| Mar 06, 2025 | $0.83 |
| Mar 07, 2025 | $0.82 |
| Mar 10, 2025 | $0.774 |
| Mar 11, 2025 | $0.762 |
| Mar 12, 2025 | $0.685 |
| Mar 13, 2025 | $0.640 |
| Mar 14, 2025 | $0.648 |
| Mar 17, 2025 | $0.695 |
| Mar 18, 2025 | $0.674 |
| 4 days before | -17.46% |
| 4 days after | -1.65% |
| On release day | -6.55% |
| Change in period | -18.82% |
| Release date | May 12, 2025 |
| Price on release | $0.352 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0100 |
| EPS surprise | 50.00% |
| Date | Price |
|---|---|
| May 06, 2025 | $0.300 |
| May 07, 2025 | $0.300 |
| May 08, 2025 | $0.305 |
| May 09, 2025 | $0.315 |
| May 12, 2025 | $0.352 |
| May 13, 2025 | $0.371 |
| May 14, 2025 | $0.346 |
| May 15, 2025 | $0.355 |
| May 16, 2025 | $0.340 |
| 4 days before | 17.37% |
| 4 days after | -3.55% |
| On release day | 5.25% |
| Change in period | 13.20% |
| Release date | Aug 11, 2025 |
| Price on release | $0.479 |
| EPS estimate | -$0.0250 |
| EPS actual | -$0.0100 |
| EPS surprise | 60.00% |
| Date | Price |
|---|---|
| Aug 05, 2025 | $0.483 |
| Aug 06, 2025 | $0.505 |
| Aug 07, 2025 | $0.514 |
| Aug 08, 2025 | $0.528 |
| Aug 11, 2025 | $0.479 |
| Aug 12, 2025 | $0.483 |
| Aug 13, 2025 | $0.500 |
| Aug 14, 2025 | $0.489 |
| Aug 15, 2025 | $0.529 |
| 4 days before | -0.725% |
| 4 days after | 10.44% |
| On release day | 0.731% |
| Change in period | 9.64% |
| Release date | Nov 06, 2025 |
| Price on release | $0.555 |
| EPS estimate | $0.0400 |
| EPS actual | -$0.0100 |
| EPS surprise | -125.00% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $0.517 |
| Nov 03, 2025 | $0.574 |
| Nov 04, 2025 | $0.616 |
| Nov 05, 2025 | $0.589 |
| Nov 06, 2025 | $0.555 |
| Nov 07, 2025 | $0.543 |
| Nov 10, 2025 | $0.581 |
| Nov 11, 2025 | $0.608 |
| Nov 12, 2025 | $0.622 |
| 4 days before | 7.41% |
| 4 days after | 12.11% |
| On release day | -2.13% |
| Change in period | 20.42% |
Harvard Bioscience Earnings Call Transcript Summary of Q3 2025
Harvard Bioscience reported Q3 2025 revenue of $20.6M (high end of guidance) with sequential revenue growth in a typically soft quarter, gross margin expansion to 58.4% and adjusted EBITDA of $2.0M. Management highlighted improved operational execution, cost reductions (about $1.4M YoY in operating expenses), positive operating cash flow (quarterly and year-to-date ~$6.8M), and net debt down to $27.5M. Product momentum included expanded SoHo Telemetry adoption, strong consumable trends for Biochrom amino acid analyzers, initial shipments of the new Incub8 Multiwell System, and increased traction for the Mesh MEA organoid platform. Backlog is the highest in nearly two years, driven by broad-based order growth across geographies and products. Management is actively negotiating credit refinancing/repayment with lenders and expects resolution in Q4, while noting potential timing risk from the U.S. government shutdown and NIH funding delays that could shift some demand into 2026. Guidance for Q4 revenue is $22.5M–$24.5M and gross margin of 58%–60%, with the lower end reflecting a potential prolonged shutdown.
